← ZEVRA THERAPEUTICS, INC. ZVRA
Market Price
$11.34
Market Cap
$660.91M
P/E Ratio
8.40
Revenue (FY 2025)
↑350.9% YoY
$106.47M
3-Yr CAGR: 116.7%
Net Income
↑178.9% YoY
$83.23M
Net Margin: 78.2%
Free Cash Flow
↑96.5% YoY
-$2.43M
FCF Yield: -0.37%
EPS (Diluted)
↑159.2% YoY
$1.35
Basic: $1.40
Return on Equity
Efficiency
53.8%
ROA: 1,189.3%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ZVRA)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | — | — | — | $-16.5M | — | $-1.13 | — | $-29.8M | $-30.4M | — |
| FY 2017 | — | — | — | $-43.4M | -162.7% | $-2.96 | -161.9% | $-33.1M | $-33.3M | -9.4% |
| FY 2018 | — | — | — | $-56.5M | -30.1% | $-3.15 | -6.4% | $-54.2M | $-54.2M | -62.9% |
| FY 2019 | $12.8M | — | $2.8M | $-24.5M | +56.6% | $-0.83 | +73.7% | $-23.7M | $-23.8M | +56.2% |
| FY 2020 | $13.3M | +3.5% | $2.3M | $-12.8M | +48.0% | $-3.21 | -286.7% | $-1.9M | $-2.0M | +91.7% |
| FY 2021 | $28.6M | +115.6% | $16.4M | $-8.6M | +33.0% | $-2.11 | +34.3% | $10.4M | $10.3M | +624.2% |
| FY 2022 | $10.5M | -63.5% | $10.1M | $-41.5M | -385.6% | — | — | $-18.7M | $-18.8M | -282.0% |
| FY 2023 | $27.5M | +162.6% | $24.5M | $-46.0M | -10.8% | — | — | $-33.5M | $-33.8M | -79.9% |
| FY 2024 | $23.6M | -14.0% | $16.2M | $-105.5M | -129.1% | $-2.28 | — | $-69.7M | $-69.7M | -105.9% |
| FY 2025 | $106.5M | +350.9% | $90.0M | $83.2M | +178.9% | $1.35 | +159.2% | $-1.6M | $-2.4M | +96.5% |
Valuation
Market Price
$11.34
Market Cap
$660.91M
Enterprise Value
$660.43M
P/E Ratio
8.40
P/B Ratio
4.33
FCF Yield
-0.37%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
84.52%
Operating Margin
59.12%
Net Margin
78.17%
Return on Equity (ROE)
53.82%
Return on Assets (ROA)
1,189.33%
Asset Turnover
15.21x
Revenue 3-Yr CAGR
116.73%
Financial Health & Liquidity
Current Ratio
0.18
Cash Ratio
1.59
Debt / Equity
0.400
Debt / Assets
8.849
Cash & Equivalents
$62.41M
Total Debt
$61.93M
Book Value / Share
$2.62
Cash Flow Efficiency
Operating Cash Flow
-$1.60M
Capital Expenditures (CapEx)
$835.00K
Free Cash Flow
-$2.43M
OCF / Revenue
-1.50%
FCF / Revenue
-2.29%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$1.35
EPS (Basic)
$1.40
Dividends / Share
N/A
Book Value / Share
$2.62
EPS YoY Growth
159.21%
Balance Sheet (FY 2025)
Total Assets
$7.00M
Total Liabilities
$39.28M
Stockholders' Equity
$154.66M
Current Assets
$7.00M
Current Liabilities
$39.28M